Stable pharmaceutical preparation containing tryptase monoclonal antibody

By adding phosphate buffer and protein protectant to trypsin-like monoclonal antibody drug preparations, the stability of the drug preparations is solved, stability and safety under different conditions are achieved, and application prospects are improved.

CN118903408AInactive Publication Date: 2024-11-08WUHAN DABAI XIAOBAI TECH CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411109600.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There are stability problems with existing trypsin-like monoclonal antibody drug preparations, especially the immune response caused by coagulation and syringe blockage, which affects the safety and effectiveness of patients.

Method used

Using a ratio containing trypsin-like monoclonal antibodies, buffers and protein protectors, control and add appropriate protein protectors through reasonable pH values, such as phosphate buffers and Tween 20, propylene glycol, trehalose, sodium chloride , methionine, polyethylene glycol form stable pharmaceutical preparations to ensure stability under low temperature, light and dilution conditions.

Benefits of technology

Good uniformity, thermal stability, light stability and freeze-thaw stability of trypsin-like monoclonal antibody preparations are achieved, which extends storage time and service life, reduces production and storage costs, and improves practicality.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903408A_ABST
    Figure CN118903408A_ABST
Patent Text Reader

Abstract

The invention relates to a stable pharmaceutical preparation containing a tryptase monoclonal antibody. The stable pharmaceutical preparation contains the tryptase monoclonal antibody, a buffer solution and a protein protective agent, the tryptase monoclonal antibody comprises a heavy chain variable region and / or a light chain variable region. Through reasonable proportioning of a buffer solution and a protein protection solution, the tryptase monoclonal antibody provided by the invention has good uniformity, thermal stability, illumination stability and freeze-thaw stability after being prepared into a pharmaceutical preparation, and still has good stability under the condition of long-term storage or dilution.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of pharmaceutical preparations, and in particular to a stable pharmaceutical preparation containing trypsin-like monoclonal antibodies. Background Art

[0002] The correlation between mast cells and their secretory products and human asthma has always been a focus of much attention. Among them, tryptase β plays an important role in human asthma and other inflammatory diseases induced by mast cells.

[0003] Many of the in vitro actions of tryptase have been summarized by administering various preparations of tryptase in the airways or skin. Studies with the Axys tryptase inhibitor, APC366, in sheep and porcine antigenic models have demonstrated a role for mast cell tryptase β in mediating airway hyperresponsiveness. In sensitized sheep, APC366 reduced early and late bronchoconstriction and blocked allergen-induced airway hyperresponsiveness.

[0004] Johnson's compound RWJ-56423, which is targeted for delivery via inhalation, was reported to have entered the clinic in 2003. Axys Pharmaceuticals is considered a pioneer in the development of mast cell tryptase inhibitors. They have proposed several classes of drugs, but many of these compounds, as well as compounds from other pharmaceutical companies, are large molecular weight / dimers and are not suitable for oral administration.

[0005] From a commercial perspective, tryptase inhibitors need to have oral bioavailability and sufficient duration of action in QD formulations to compete effectively in the market. Many academic groups have also developed large molecular weight tryptase dimer inhibitors, including highly basic functionalities such as amidines and guanidines. However, their high molecular weight generally precludes their development as oral drugs.

[0006] Targeted biologics therapy can benefit AR patients who are not well controlled by traditional treatments. A Phase IIb study for moderate to severe asthma showed that IL-4Rα-targeted monoclonal antibodies can significantly improve patients' nasal symptoms and improve their quality of life. The clarification of the appropriate population and medication regimen for biologics treatment will bring new pollen-season treatment options and efficacy experience to SAR patients. The use of specific monoclonal antibodies to block the function of tryptase targets can effectively control the occurrence, development, invasion and metastasis of tryptase. Because antibody molecules have complex protein multi-level structures and are easy to physically bond together, which may lead to undesirable immune responses, or may clog syringes or pumps during administration and be unsafe for patients, one of the problems that liquid preparations of antibodies have long faced is the stability problem caused by aggregation.

[0007] Therefore, there is a need for pharmaceutical formulations of human trypsin monoclonal antibodies with stability and consistent quality. Summary of the invention

[0008] The object of the present invention is to provide a stable pharmaceutical preparation containing trypsin-like monoclonal antibodies, which has good stability and quality consistency and has good application prospects.

[0009] To this end, in a first aspect, the present invention provides a pharmaceutical preparation, which comprises a trypsin-like monoclonal antibody, a buffer, and a protein protectant; the trypsin-like monoclonal antibody comprises a heavy chain variable region and / or a light chain variable region;

[0010] Wherein, the heavy chain variable region may comprise the following CDR sequence:

[0011] CDR1 having the amino acid sequence shown in SEQ ID NO: 1;

[0012] CDR2 having the amino acid sequence shown in SEQ ID NO: 2;

[0013] CDR3 having the amino acid sequence shown in SEQ ID NO: 3;

[0014] The light chain variable region may comprise a CDR sequence as shown below:

[0015] CDR1 having the amino acid sequence shown in SEQ ID NO: 4;

[0016] CDR2 having the amino acid sequence shown in SEQ ID NO: 5;

[0017] CDR3 having the amino acid sequence shown in SEQ ID NO:6.

[0018] In some embodiments, the tryptase monoclonal antibody is a human-mouse chimeric tryptase monoclonal antibody.

[0019] In some embodiments, the heavy chain variable region of the tryptase monoclonal antibody comprises the amino acid sequence shown in SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:10.

[0020] In some embodiments, the light chain variable region of the tryptase monoclonal antibody comprises the amino acid sequence shown in SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13 or SEQ ID NO:14.

[0021] In some embodiments, the pharmaceutical preparation has a pH of 5.0 to 8.0. Preferably, the pharmaceutical preparation has a pH of 5.5 to 7.5.

[0022] In some embodiments, the concentration of the tryptase monoclonal antibody in the pharmaceutical preparation is 1 to 40 mg / ml. Preferably, the concentration of the tryptase monoclonal antibody in the pharmaceutical preparation is 10 to 30 mg / ml, more preferably 20 mg / ml.

[0023] In some embodiments, the buffer in the pharmaceutical preparation is selected from one or more of a citrate buffer and a phosphate buffer. Preferably, the buffer is selected from a phosphate buffer.

[0024] In some embodiments, the concentration of the buffer is 5 to 25 mmol / L. Preferably, the concentration of the phosphate buffer is 5 to 15 mmol / L, more preferably 10 mmol / L.

[0025] In some embodiments, the protein protective agent in the pharmaceutical preparation is selected from one or more of surfactants, polyol dispersants, sugars, salts, amino acids, and polymers. Preferably, the protein protective agent includes ribose.

[0026] In some embodiments, the concentration of the protein protective agent in the pharmaceutical preparation may be 10 to 200 mg / ml. Preferably, the concentration of the protein protective agent in the pharmaceutical preparation is 30 to 70 mg / ml, more preferably 50 mg / ml.

[0027] In some embodiments, the pharmaceutical preparation is stable under low temperature conditions for at least 24 months. In some embodiments, the temperature of the low temperature conditions is 2-8°C.

[0028] In some embodiments, after the pharmaceutical preparation is diluted 2-80 times with a diluent, it can still be stable for at least 7 days at a temperature of 25±2°C.

[0029] In some embodiments, the diluent includes 0.9% NaCl aqueous solution, ie, normal saline.

[0030] In some embodiments, the pharmaceutical formulation is stable for up to 30 days at an illumination of not less than 4500 lux and a temperature of 37±2°C.

[0031] In some embodiments, the pharmaceutical formulation is a nasal spray.

[0032] In another aspect, the present invention provides use of the pharmaceutical preparation in preparing a drug for treating tryptase-related diseases.

[0033] In some embodiments, the disease comprises at least one selected from a pulmonary disease, an autoimmune disease, an inflammatory disease, a fibrotic disease, a granulocytic (such as basophilic) disease, a monocytic disease, a lymphocytic disease, or a disease associated with an increase in the number or distribution of normal or abnormal tissue resident cells (such as mast cells, macrophages or lymphocytes) or stromal cells (such as fibroblasts, myofibroblasts, smooth muscle cells, epithelial cells or endothelial cells).

[0034] In some embodiments, the disease comprises a pulmonary disease.

[0035] In some embodiments, the pulmonary disease comprises at least one selected from asthma, airway hyperresponsiveness, and chronic obstructive pulmonary disease (COPD).

[0036] In some embodiments, the pulmonary disease comprises asthma.

[0037] In some embodiments, the asthma is high Th2 asthma or low Th2 asthma.

[0038] In some embodiments, the autoimmune disease comprises at least one selected from rheumatoid arthritis, psoriasis, eosinophilic esophagitis, inflammatory bowel disease (IBD), and Crohn's disease.

[0039] In some embodiments, the inflammatory disease comprises at least one selected from chronic idiopathic urticaria (CIU, also known as chronic spontaneous urticaria, CSU), anaphylaxis, allergic shock, atopic dermatitis, or allergic rhinitis.

[0040] In some embodiments, the fibrotic disease is idiopathic pulmonary fibrosis (IPF).

[0041] In some embodiments, the disease includes a disease associated with an increase in the number or distribution of normal or abnormal tissue resident cells (such as mast cells, macrophages or lymphocytes) or stromal cells (such as fibroblasts, myofibroblasts, smooth muscle cells, epithelial cells or endothelial cells).

[0042] In some embodiments, the disease comprises mastocytosis.

[0043] Compared with the prior art, the present invention has at least the following beneficial effects:

[0044] The present invention provides a pharmaceutical preparation containing a trypsin-like monoclonal antibody. By rationally matching a buffer and a protein protection solution, the trypsin-like monoclonal antibody provided by the present invention is prepared into the pharmaceutical preparation, and has good uniformity, thermal stability, light stability, and freeze-thaw stability, and can still have good stability under the condition of long-term storage or dilution. It can better meet the needs of practical applications, reduce the difficulty and cost of the trypsin-like monoclonal antibody pharmaceutical preparation in storage, improve practicality, and has good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Various other advantages and benefits will become apparent to those of ordinary skill in the art by reading the detailed description of the preferred embodiments below. The accompanying drawings are only used for the purpose of illustrating the preferred embodiments and are not to be considered as limiting the present invention. In the accompanying drawings:

[0046] Figure 1 The protein purity measured by SDS-PAGE over time for formulations containing trypsin monoclonal antibody and different buffers in an accelerated thermal stability test;

[0047] Figure 2 The protein purity measured by SDS-PAGE over time for formulations containing trypsin monoclonal antibody and different buffers in the photostability test;

[0048] Figure 3 The protein purity measured by SDS-PAGE method changes over time for formulations containing trypsin monoclonal antibody, phosphate buffer and different protein protectants in an accelerated thermal stability test;

[0049] Figure 4 The protein purity of the preparations containing trypsin monoclonal antibody, phosphate buffer and different protein protectants measured by SDS-PAGE method changes over time in the light stability test;

[0050] Figure 5 The protein purity of the preparations containing trypsin monoclonal antibody, phosphate buffer and different protein protectants measured by SDS-PAGE method changes over time in freeze-thaw stability test;

[0051] Figure 6 The protein concentration of the three groups of AC preparations of the present invention changes over time in the long-term stability test;

[0052] Figure 7 The figure shows the changes in antibody protein concentrations of five groups of AE preparations of the present invention at different dilutions over time in the dilution stability test. DETAILED DESCRIPTION

[0053] The exemplary embodiments of the present disclosure will be described in more detail below with reference to the accompanying drawings. Although the exemplary embodiments of the present disclosure are shown in the accompanying drawings, it should be understood that the present disclosure can be implemented in various forms and should not be limited by the embodiments described herein. On the contrary, these embodiments are provided in order to enable a more thorough understanding of the present disclosure and to fully convey the scope of the present disclosure to those skilled in the art.

[0054] Unless otherwise indicated, the examples herein employ conventional techniques of molecular biology, microbiology, cell biology, biochemistry, and immunology within the skill of the art.

[0055] Unless otherwise specified, the terms used in this application have the meanings commonly understood by those skilled in the art.

[0056] definition

[0057] Antibody

[0058] As used herein, the term "monoclonal antibody" refers to an antibody population containing uniform or substantially uniform single antibodies. Monoclonal antibodies can be obtained from a single hybridoma cell clone (Milstein, C (1999). "The hybridoma revolution: an offshoot of basic research". BioEssays. 21 (11): 966-73). A complete monoclonal antibody contains two heavy chains and two light chains. Each heavy chain consists of a heavy chain variable region (VH) and the first, second and third heavy chain constant regions (CH1, CH2, CH3), while each light chain consists of a light chain variable region (VL) and a light chain constant region (CL). The VH and VL regions of the heavy and light chains also each have three complementary determining regions (CDRs), and the three CDRs are separated by a continuous portion called a framework region (FR), which is more highly conserved than the CDRs and forms a scaffold to support the hypervariable loop. The six CDRs of a heavy chain and a light chain together constitute the antigen binding site of the antibody, which determines the specificity of the antibody. The monoclonal antibodies described herein also include fragments or derivatives of the intact monoclonal antibodies that have antigen binding function. The fragments or derivatives have the same antigen binding specificity as the intact monoclonal antibodies, but the affinity of the fragments or derivatives binding to their specific antigens may be the same as or different from that of the intact monoclonal antibodies.

[0059] In some embodiments, the monoclonal antibodies described herein include antigen-binding fragments. Antigen-binding fragments refer to one or more antibody fragments that retain the ability to specifically bind to an antigen. Examples of antigen-binding fragments include, but are not limited to, (i) Fab fragments, which refer to monovalent fragments consisting of VL, VH, CL and CH1 domains; (ii) Fab′ fragments, which refer to Fab fragments containing a portion of the hinge region; (iii) F(ab′)2 fragments, which refer to bivalent fragments containing two Fab fragments linked by a disulfide bond in the hinge region; (iv) Fd fragments consisting of VH and CH1 domains; (v) Fv fragments consisting of the VL and VH domains of a single arm of an antibody, (vi) dAb fragments (Ward et al., Nature 341:544-546 (1989); PCT Publication WO 90 / 05144), which contain a single variable domain; (vii) isolated CDRs; (viii) single-chain Fv fragments, which refer to monovalent fragments in which the VL and VH domains are directly linked or connected by a peptide chain (Huston JS et al., Proc Natl Acad Sci USA, 85:5879 (1988)).

[0060] In some embodiments, the monoclonal antibodies described herein include chimeric monoclonal antibodies, a portion of which heavy and / or light chains are identical or homologous to corresponding sequences of antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remaining chains are identical or homologous to corresponding sequences of antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they exhibit the desired functional activity.

[0061] In some embodiments, the monoclonal antibodies described herein include human-mouse chimeric monoclonal antibodies having murine heavy and light chain variable regions and human heavy and light chain constant regions.

[0062] In some embodiments, the monoclonal antibodies described herein include humanized monoclonal antibodies. The humanized form of a non-human source (e.g., mouse) antibody is a chimeric immunoglobulin, immunoglobulin chain, or fragment thereof (e.g., Fv, Fab, Fab', F(ab')2, or other antigen-binding sequences of an antibody) containing a minimum of sequences obtained from a non-human immunoglobulin. In some examples, a humanized antibody may be a CDR-grafted antibody, in which the amino acid sequence of a human CDR is introduced into the amino acid sequence of a non-human VH and VL to replace the amino acid sequence of the corresponding non-human CDR. In other examples, most of the amino acid sequence of a humanized antibody may be derived from a human immunoglobulin (receptor antibody), in which the amino acid residues of the CDR of the receptor are replaced by the amino acid residues of the CDR of a non-human (e.g., mouse, rat, rabbit) antibody having the desired specificity, affinity, and ability. Typically, humanized antibodies substantially comprise at least one, generally two variable domains, wherein all or substantially all CDR regions correspond to the sequence of a non-human immunoglobulin, and all or substantially all framework (FR) regions are sequences of human immunoglobulins. In some examples, the framework region residues of the variable region of a human immunoglobulin are replaced by corresponding non-human residues. Moreover, humanized antibodies may include residues that are not present in both the recipient antibody and the imported CDR or framework region sequences.

[0063] The tryptase monoclonal antibody described herein refers to a monoclonal antibody that can specifically bind to the tryptase protein.

[0064] Unless otherwise indicated, as used herein, the term "tryptase β" refers to any tryptase β from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). Tryptase β is a serine protease as the main component of mast cell secretory granules. As used herein, the term encompasses tryptase β1 (encoded by the TPSAB1 gene, which also encodes tryptase α1), tryptase β2 (encoded by the TPSB2 gene), and tryptase β3 (also encoded by the TPSB2 gene). Exemplary human trypsin β1 sequences are shown in SEQ ID NO: 15 (see also GenBank accession number NP_003285.2). Exemplary human trypsin β2 sequences are shown in SEQ ID NO: 16 (see also GenBank accession number AAD13876.1). Exemplary human trypsin β3 sequences are shown in SEQ ID NO: 17 (see also GenBank accession number NP_077078.5). The term "tryptase β" encompasses "full-length" unprocessed tryptase β and tryptase β produced by post-translational modification (including proteolytic processing). It is believed that the full-length, original tryptase β is processed in two proteolytic steps. First, autocatalytic intermolecular shearing occurs at R-3, especially at acidic pH and in the presence of polyanions (e.g., heparin or dextran sulfate). Then, the remaining pro dipeptide is removed (possibly by dipeptidyl peptidase I). For full-length human trypsin β1, with reference to the following sequence, the underlined amino acid residues correspond to the native leader sequence, and the bold and gray-shaded amino acid residues correspond to the pro domain, which is cut to form a mature protein (see, e.g., Sakai et al. J. Clin. Invest. 97: 988-995, 1996)

[0065] MLNLLLLALPVLASR AYAAPAPGQALQRVGIVGGQEAPRSKWPWQVSLRVHGPYWMHFCGGSLIHPQWVLTAAHCVGPDVKDLAALRVQLREQHLYYQDQLLPVSRIIVHPQFYTAQIGADIALLELEEPVNVSSHVHTVTLPPASE TFPGMPCWVTGWGDVDNDERLPPPFPLKQVKVPIMENHICDAKYHLGAYTGDDVRIVRDDMLCAGNTRRDSCQGDSGGPLVCKVNGTWLQAGVVSWGEGCAQPNRPGIYTRVTYYLDWIHHYVPKKP(SEQ ID NO: 18).

[0066] In some embodiments, the tryptase monoclonal antibody described herein comprises a heavy chain CDR sequence selected from the amino acid sequences shown in SEQ ID NOs: 1, 2, and 3. In some embodiments, the tryptase monoclonal antibody described herein comprises a light chain CDR sequence selected from the amino acid sequences shown in SEQ ID NOs: 4, 5, and 6.

[0067] In some embodiments, the tryptase monoclonal antibodies described herein include a heavy chain variable region V H , the heavy chain variable region V H The heavy chain CDR sequence comprises the following: CDR1 with the amino acid sequence shown in SEQ ID NO: 1, CDR2 with the amino acid sequence shown in SEQ ID NO: 2, and CDR3 with the amino acid sequence shown in SEQ ID NO: 3.

[0068] In some embodiments, the tryptase monoclonal antibodies described herein include a light chain variable region V L , the light chain variable region V L It comprises the light chain CDRs as shown below: CDR1 with the amino acid sequence shown in SEQ ID NO:4, CDR2 with the amino acid sequence shown in SEQ ID NO:5, and CDR3 with the amino acid sequence shown in SEQ ID NO:6.

[0069] In some embodiments, the tryptase monoclonal antibodies described herein include a heavy chain variable region V H and light chain variable region V L , the heavy chain variable region V H comprising a CDR1 having an amino acid sequence as shown in SEQ ID NO: 1, a CDR2 having an amino acid sequence as shown in SEQ ID NO: 2, and a CDR3 having an amino acid sequence as shown in SEQ ID NO: 3; the light chain variable region V L It comprises a CDR1 having an amino acid sequence as shown in SEQ ID NO:4, a CDR2 having an amino acid sequence as shown in SEQ ID NO:5, and a CDR3 having an amino acid sequence as shown in SEQ ID NO:6.

[0070] In some embodiments, the trypsin monoclonal antibody described herein comprises a heavy chain variable region V having an amino acid sequence as shown in SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 or SEQ ID NO: 10. HIn some embodiments, the trypsin-like monoclonal antibodies described herein include a light chain variable region V having an amino acid sequence as shown in SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, or SEQ ID NO: 14. L In some embodiments, the tryptase monoclonal antibody described herein comprises a heavy chain variable region V having an amino acid sequence as shown in SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 or SEQ ID NO: 10. H and a light chain variable region V having an amino acid sequence as shown in SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 14. L .

[0071] In some embodiments, the trypsin-like monoclonal antibody described herein further comprises an immunoglobulin constant region. In some embodiments, the immunoglobulin constant region comprises a heavy chain and / or a light chain constant region. The heavy chain constant region comprises C H1 , C H1-CH2 or C H1-CH3 region, the light chain constant region comprising C L In some embodiments, the heavy chain constant region is of type IgG1.

[0072] Table 1 below lists exemplary amino acid sequences in some embodiments:

[0073] Table 1 Exemplary amino acid sequences

[0074]

[0075] In some embodiments, the strain expressing the tryptase monoclonal antibody described in the present invention is preserved, classified and named as hybridoma cell line TYP 3C4 (Hybridoma cell line TYP 3C4), with a preservation number of CCTCCNO: C2024194, and was preserved in the China Center for Type Culture Collection on July 23, 2024, and the preservation address is: Wuhan, China; the strain expresses the tryptase monoclonal antibody of the present invention, the heavy chain variable region sequence comprises the CDR sequence shown in SEQ ID NO: 1 to 3, the heavy chain constant region type is IgG1, the light chain variable region comprises the CDR sequence shown in SEQ ID NO: 4 to 6, and the light chain constant region sequence type is IgG1.

[0076] In some embodiments, the tryptase monoclonal antibody of the present invention is expressed by the hybridoma cell line TYP3C4.

[0077] The present invention relates to a pharmaceutical preparation comprising a tryptase monoclonal antibody. In some embodiments, the pharmaceutical preparation of the present invention may comprise the tryptase monoclonal antibody at a concentration of 1 to 40 mg / ml. In some embodiments, the concentration of the tryptase monoclonal antibody is any concentration value within the above range.

[0078] Buffer

[0079] As used herein, the term "buffer" refers to a buffer solution that tolerates changes in pH through the action of its acid-base conjugate components. As used herein, "buffer" refers to a compound solution that is known to be safely used in pharmaceutical preparations and has the ability to maintain or control the pH of the preparation within the desired range. Acceptable buffers that can control the pH value in the range of mildly acidic pH to mildly alkaline pH (e.g., pH 5.0 to 8.0) include, but are not limited to, one or a combination of any of phosphate buffer, acetate buffer, citrate buffer, arginine buffer, 2-amino-2-hydroxymethyl-1,3-propanediol (TRIS) buffer, histidine buffer, etc.

[0080] Examples of buffers that can control the pH value of the pharmaceutical preparation within a desired range include histidine buffer, citrate buffer, phosphate buffer, and other organic acid or inorganic acid buffers. These buffers can be used alone or in combination of two or more. Preferably, the pharmaceutical preparation of the present invention comprises a histidine buffer, a citrate buffer, or a phosphate buffer. More preferably, the pharmaceutical preparation of the present invention comprises a histidine buffer.

[0081] "Histidine buffer" is a buffer containing histidine ions. The histidine buffer may include one or more of histidine, histidine hydrochloride, histidine acetate, histidine phosphate, histidine sulfate, etc. In some embodiments, the histidine buffer may be a histidine-histidine hydrochloride buffer. In some embodiments, the pH value of the histidine buffer may be any pH value in the range of 5.5 to 6.5.

[0082] "Citrate buffer" is a buffer containing citrate ions. The citric acid buffer may contain one or more of citric acid, monosodium citrate, disodium citrate, trisodium citrate, monopotassium citrate, dipotassium citrate, tripotassium citrate, sodium chloride, potassium chloride, etc. In some embodiments, the citric acid buffer is a citric acid-trisodium citrate buffer. In some embodiments, the pH of the citric acid buffer may be any pH value in the range of 5.0 to 5.5.

[0083] "Phosphate buffer" is a buffer containing phosphate ions. The phosphate buffer may contain one or more of sodium dihydrogen phosphate, potassium dihydrogen phosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, sodium chloride, potassium chloride, etc. In some embodiments, the phosphate buffer is sodium dihydrogen phosphate-disodium hydrogen phosphate buffer. In some embodiments, the pH of the phosphate buffer may be any pH value in the range of 6.5 to 8.0.

[0084] The concentration of the buffer described herein refers to the concentration of the buffer ions in the buffer. In some embodiments, the concentration of a suitable buffer for the pharmaceutical preparation of the present invention may be 5 to 25 mmol / L. In some embodiments, the concentration of the buffer is any concentration value within the above range.

[0085] Protein Protectant

[0086] As used herein, the term "protein protective agent" refers to an agent that, when combined with a protein of interest, can prevent or reduce the chemical and / or physical instability of the protein. Examples of protein protective agents include one or more of surfactants, polyol dispersants, sugars, salts, amino acids, and polymers. Examples of surfactants include Tween surfactants (represented by tween-80) and Triton surfactants (represented by triton-100). Examples of polyol dispersants include propylene glycol, glycerol, and the like. Examples of sugars include glucose, sucrose, trehalose, lactose, dextran, ribose, and the like. Examples of salts include sodium sulfate, sodium glutamate, sodium chloride, potassium chloride, ammonium acetate, and the like. Examples of amino acids include valine, isoleucine, leucine, phenylalanine, methionine, tryptophan, threonine, lysine, and the like. Examples of polymers include polyethylene glycol, povidone, and the like.

[0087] In some embodiments, the protein protective agent used in the pharmaceutical formulation of the present invention is selected from surfactants, polyol dispersants, sugars, salts, amino acids, polymers, or combinations thereof.

[0088] In some embodiments, the concentration of the protein protective agent used in the pharmaceutical preparation of the present invention may be 10 to 200 mg / ml. In some embodiments, the concentration of the protein protective agent is any concentration value within the above range.

[0089] disease

[0090] As used herein, "disease" is any disease that will benefit from antibody (e.g., any anti-tryptase antibody described herein) treatment. This includes chronic and acute conditions or diseases, including those pathological diseases that make mammals susceptible to the conditions discussed. In some embodiments, the disease is a lung disease, autoimmune disease, inflammatory disease, fibrotic disease, granulocytic (basophilic) disease, monocytic disease, lymphocytic disease, or a disease associated with an increase in the number or distribution of resident cells (such as mast cells, macrophages or lymphocytes) or stromal cells (such as fibroblasts, myofibroblasts, smooth muscle cells, epithelial cells or endothelial cells) of normal or abnormal tissues. In some embodiments, the disease is a lung disease. In some examples, the disease can be a tryptase-related disease or a tryptase-mediated disease. The terms "tryptase-related disease" and "tryptase-mediated disease" refer to any disease or condition mediated by or associated with tryptase. In some embodiments, tryptase-mediated diseases are associated with excessive tryptase levels or activity, wherein atypical symptoms may manifest locally and / or systemically in the body due to the tryptase levels or activity.

[0091] In some embodiments, pulmonary disease is asthma. In some embodiments, asthma is persistent chronic severe asthma with acute events (exacerbations or sudden attacks) of symptom exacerbation that may threaten life. In some embodiments, asthma is atopic (also referred to as allergic) asthma, non-allergic asthma (e.g., often infected by respiratory viruses (e.g., influenza, parainfluenza, rhinovirus, human metapneumovirus and respiratory syncytial virus) or inhaled irritants (atmospheric pollutants, smog, diesel particles, volatile chemicals and indoor or outdoor gases or even due to dry cold air)) triggered.

[0092] In some embodiments, the autoimmune disease, inflammatory disease, fibrotic disease, granulocytic (basophilic) disease, monocytic disease, or lymphocytic disease is esophagitis (e.g., eosinophilic esophagitis), allergic rhinitis, non-allergic rhinitis, sinusitis with polyps, nasal polyps, bronchitis, chronic pneumonia, allergic bronchopulmonary aspergillosis, airway inflammation, allergic rhinitis, bronchiectasis, and / or chronic bronchitis.

[0093] In some embodiments, the disease is an inflammatory disease of the skin. In some embodiments, the disease is atopic dermatitis or onchocercal dermatitis. In some embodiments, the disease is chronic idiopathic urticaria (CIU or CSU). Or colitis in celiac disease, food allergies, gastritis, gastroenteritis, infectious gastritis or enterocolitis (e.g., chronic active gastritis infected by Helicobacter pylori), esophagitis and other forms of gastrointestinal inflammation or undetermined colitis caused by infectious agents.

[0094] In some embodiments, pulmonary disease, autoimmune disease, inflammatory disease, fibrotic disease, neutrophilic disease or eosinophilic disease is chronic obstructive pulmonary disease (COPD). In some embodiments, COPD is the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) category A. In some embodiments, COPD is GOLD category B. In some embodiments, COPD is GOLD category C. In some embodiments, COPD is GOLD category D. In some embodiments, COPD is chronic bronchitis. In some embodiments, COPD is emphysema. In some embodiments, emphysema is proximal alveolar, panlobular or distal alveolar emphysema. In some embodiments, emphysema is cigarette-induced emphysema. In some embodiments, COPD is associated with exposure to particulate dust, chemical fumes and / or air pollution. In some embodiments, COPD is associated with impaired lung development. In some embodiments, COPD is chronic obstructive asthma. In some embodiments, COPD is associated with alpha-1 antitrypsin deficiency. In some embodiments, COPD is associated with disruption of serine protease inhibitor clade E member 2 (SERPINE2). In some embodiments, COPD is COPD with persistent systemic inflammation. In some embodiments, COPD is eosinophilic or high helper T cell type 2 (TH2) COPD. In some embodiments, COPD is COPD with persistent bacterial colonization. In some embodiments, COPD is frequently exacerbated COPD. In some embodiments, autoimmune diseases, inflammatory diseases, fibrotic diseases, neutrophilic diseases, or eosinophilic diseases are asthma-COPD overlap syndrome (ACOS). In some embodiments, ACOS is eosinophil-dominant, neutrophil-dominant, mixed mode, or non-inflammatory (granulocytopenic) ACOS. In some embodiments, autoimmune diseases, inflammatory diseases, fibrotic diseases, neutrophilic diseases, or eosinophilic diseases are COPD-obstructive sleep apnea (OSA) overlap syndrome.

[0095] The above list is not all-inclusive, and the skilled artisan will appreciate that a disease or disorder may fall within a variety of classifications.

[0096] Example 1: Effect of buffer on formulation stability

[0097] In this embodiment, the following three groups of different buffers were selected to prepare a pharmaceutical preparation containing a tryptase monoclonal antibody (expressed by a hybridoma cell line TYP 3C4 with a deposit number of CCTCC NO: C2024194) at a concentration of 20.0 mg / ml, and the prepared pharmaceutical preparation was used for accelerated thermal stability test (the pharmaceutical preparation was stored at 42±2°C for 4 weeks, and samples were taken at 0, 1, 2, 3, and 4 weeks respectively) and light stability test (the pharmaceutical preparation was stored at 4±2°C at an illumination of 4500±500 lux for 4 weeks, and samples were taken at 0, 1, 2, 3, and 4 weeks respectively). The protein purity was measured by SDS-PAGE or UV-visible spectrophotometry (detection wavelength: 280 nm).

[0098] Table 2 Accelerated thermal stability test results of preparations using different buffers

[0099]

[0100]

[0101] The results of the accelerated thermal stability test are shown in Table 2 and Figure 1 As shown, it can be seen that the pH value fluctuations of the preparations in the three experimental groups were small within 4 weeks under the test conditions, indicating that the three buffers all have sufficient pH buffering capacity. In addition, the protein purity of the preparations in the three experimental groups under the test conditions decreased within 4 weeks, indicating that the preparations should be stored at low temperatures. The preparation containing phosphate buffer in experimental group 1 had the smallest decrease in protein purity after 4 weeks, indicating that phosphate buffer has the best protection for trypsin monoclonal antibodies.

[0102] Table 3 Light stability test results of preparations using different buffers

[0103]

[0104] The results of the light stability test are shown in Table 3 and Figure 2 As shown, it can be seen that the pH value fluctuations of the preparations in the three experimental groups were small within 4 weeks under the test conditions, indicating that the three buffers all have sufficient pH buffering capacity. In addition, the protein purity of the preparations in the three experimental groups under the test conditions decreased within 4 weeks, indicating that the preparations should be stored away from light. The preparation containing phosphate buffer in experimental group 1 had the smallest decrease in protein purity after 4 weeks, indicating that phosphate buffer has the best protection for trypsin monoclonal antibodies.

[0105] Example 2 Effect of protein protective agent on formulation stability

[0106] According to the test results of Example 1, 10 mM phosphate buffer was selected, and this example continued to study the effect of the protein protective agent on the stability of the preparation on this basis.

[0107] Six different protein protectants were selected to prepare a pharmaceutical preparation containing a tryptase monoclonal antibody at a concentration of 20.0 mg / ml and a phosphate buffer at a concentration of 10 mmol / L at a pH of 7.0. The protein protectants used in each group and their concentrations are shown in Table 4. The prepared pharmaceutical preparations were subjected to accelerated thermal stability test, light stability test and freeze-thaw stability test (the pharmaceutical preparations were subjected to four cycles, each cycle at -20±2°C for 3 days, then at 25±2°C for 4 days, and samples were taken at 0, 1, 2, 3, and 4 weeks, respectively).

[0108] The results of the accelerated thermal stability tests are shown in Table 5 and Figure 3 The obtained light stability test results are shown in Table 6 and Figure 4 The freeze-thaw stability test results are shown in Tables 7 and Figure 5 The protein purity was measured by SDS-PAGE or UV-visible spectrophotometry (detection wavelength: 280 nm).

[0109] Table 4 Preparations containing trypsin monoclonal antibody, phosphate buffer and different protein protective agents

[0110]

[0111] Table 5 Protein purity determination results in accelerated thermal stability test of preparations using different protein protective agents (%)

[0112]

[0113]

[0114] From Table 5 and Figure 3 It can be seen that the protein purity of the preparations in the six experimental groups decreased within 4 weeks under the test conditions, indicating that the preparations should be stored at low temperatures. The preparation containing Tween 20, propylene glycol, trehalose, sodium chloride, methionine, and polyethylene glycol in experimental group 3 showed the smallest decrease in protein purity after 4 weeks, indicating that protein protectant 3 has the best protection for trypsin monoclonal antibodies.

[0115] Table 6 Protein purity determination results in light stability test of preparations using different protein protective agents (%)

[0116] Time Experimental Group 1 Experimental Group 2 Experimental Group 3 Experimental Group 4 Experimental Group 5 Experimental Group 6 Control group 0 Weeks 96.6 96.6 96.8 96.6 96.6 96.8 96.6 1 week 96.5 96.5 96.7 96.5 96.5 96.7 96.5 2 weeks 96.1 95.8 96.5 96.3 96.3 96.1 95.8 3 weeks 95.8 95.2 96.2 96.1 95.9 95.7 95.2 4 weeks 95.3 95.1 96 95.5 95.5 95.2 94.7 Reduce the amount 1.3 1.5 0.8 1.1 1.1 1.6 1.9

[0117] From Table 6 and Figure 4 It can be seen that the protein purity of the preparations in the six experimental groups decreased within 4 weeks under the test conditions, indicating that the preparations should be stored away from light. The preparation containing Tween 20, propylene glycol, trehalose, sodium chloride, methionine, and polyethylene glycol in experimental group 3 showed the smallest decrease in protein purity after 4 weeks, indicating that protein protectant 3 has the best protection for trypsin monoclonal antibody.

[0118] Table 7 Protein purity determination results in freeze-thaw stability test of preparations using different protein protective agents (%)

[0119] Time Experimental Group 1 Experimental Group 2 Experimental Group 3 Experimental Group 4 Experimental Group 5 Experimental Group 6 Control group 0 Weeks 96.7 96.6 96.6 96.7 96.6 96.6 96.6 1 week 96.6 96.5 96.6 96.6 96.5 96.5 96.5 2 weeks 96.5 96.4 96.5 96.5 96.4 96.4 96.3 3 weeks 96.4 96.2 96.4 96.3 96.2 96.2 96.1 4 weeks 96.2 96.1 96.3 96.1 96.1 96 95.9 Reduce the amount 0.5 0.5 0.3 0.6 0.5 0.6 0.7

[0120] From Table 7 and Figure 5 It can be seen that the protein purity of the preparations in the six experimental groups decreased within 4 weeks under the test conditions, indicating that the preparations should avoid repeated freezing and thawing. The preparation containing Tween 20, propylene glycol, trehalose, sodium chloride, methionine, and polyethylene glycol in experimental group 3 showed the smallest decrease in protein purity after 4 weeks, indicating that protein protectant 3 has the best protection for trypsin monoclonal antibody.

[0121] Example 3 Long-term stability of protein formulations

[0122] Three batches of preparations were prepared using trypsin monoclonal antibody, phosphate buffer, Tween 20, propylene glycol, trehalose, sodium chloride, methionine, and polyethylene glycol, and were named Group A, Group B, and Group C, respectively, wherein the concentration of trypsin monoclonal antibody was 20.0 mg / ml, the concentration of phosphate buffer was 10 mmol / L, the concentration of Tween 20 was 1 mg / ml, the concentration of propylene glycol was 1 mg / ml, the concentration of trehalose was 50 mg / ml, the concentration of sodium chloride was 9 mg / ml, the concentration of methionine was 9 mg / ml, the concentration of polyethylene glycol was 3 mg / ml, and the pH of the preparation was 7.4. The three groups of preparations were tested for long-term stability, and the results are listed in Tables 8 and 9. Figure 6 The preparation is placed in an ampoule, the bottle mouth is sealed with a bromobutyl rubber stopper, and the bottle mouth is fastened with an aluminum-plastic composite cover. The preparation is stored in a sealed container at 2-8°C and protected from light for 2 years. Samples are taken regularly at 0, 3, 6, 9, 12, 18 and 24 months to test the protein concentration and purity of the preparation. The protein purity is measured by SDS-PAGE or UV-visible spectrophotometry (detection wavelength: 280nm).

[0123] Table 8 Long-term stability test results of the preparations

[0124]

[0125] From Table 8 and Figure 6It can be seen that at the end of the 2-year test, the protein concentration and purity of the three groups of preparations ABC did not change significantly; the measured protein purity decreased by 0.1%, 0.2% and 0.4%, respectively, all meeting the preset standards; the change in binding activity also met the preset standards. This shows that the preparation of the present invention can be stably stored at 2-8°C for 2 years.

[0126] Example 4 Dilution stability of protein preparations

[0127] The preparations were prepared according to Example 3, and the preparations were diluted with 0.9% NaCl saline to reduce the antibody concentration in the preparations from 20.0 mg / ml to 0.5, 1.0, 2.0, 5.0 and 10.0 mg / ml. The diluted preparations were groups A, B, C, D and E. The stability of the diluted preparations was measured under the dilution stability test conditions. The results are shown in Tables 9 and Figure 7 The preparation was diluted with 0.9% NaCl saline and stored at room temperature 25±2°C for 7 days. Samples were taken regularly on days 0, 1, 2, and 7 to test the protein concentration and purity of the preparation.

[0128] Table 9 Dilution stability test results of the preparations

[0129]

[0130] From Table 9 and Figure 7 It can be seen that after dilution, the protein concentration and purity of the five AE preparations did not change significantly; this indicates that the preparations of the present invention can be stably stored at 25±2°C for at least 7 days after being diluted 2 to 80 times with 0.9% saline.

[0131] In summary, the preparation provided by the present invention can better maintain the stability of tryptase monoclonal antibody. In order to better maintain the stability of the antibody, the preparation of the present invention is preferably stored at a temperature of 2-8°C in the dark.

[0132] The above is only a preferred specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any changes or substitutions that can be easily thought of by a person skilled in the art within the technical scope disclosed by the present invention should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention shall be based on the protection scope of the claims.

Claims

1. A pharmaceutical preparation, It is characterized in that It comprises a trypsin-like monoclonal antibody, a buffer, and a protein protective agent; the trypsin-like monoclonal antibody comprises a heavy chain variable region and / or a light chain variable region; Wherein, the heavy chain variable region may comprise the following CDR sequence: CDR1 having the amino acid sequence shown in SEQ ID NO: 1; CDR2 having the amino acid sequence shown in SEQ ID NO: 2; CDR3 having the amino acid sequence shown in SEQ ID NO: 3; The light chain variable region may comprise a CDR sequence as shown below: CDR1 having the amino acid sequence shown in SEQ ID NO: 4; CDR2 having the amino acid sequence shown in SEQ ID NO: 5; CDR3 having the amino acid sequence shown in SEQ ID NO:

6.

2. The pharmaceutical preparation according to claim 1, It is characterized in that The heavy chain variable region of the tryptase monoclonal antibody comprises the amino acid sequence shown in SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:

10.

3. The pharmaceutical preparation according to claim 1, It is characterized in that The light chain variable region of the trypsin-like monoclonal antibody comprises an amino acid sequence as shown in SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13 or SEQ ID NO:

14.

4. The pharmaceutical preparation according to claim 1, It is characterized in that The tryptase monoclonal antibody is a human-mouse chimeric tryptase monoclonal antibody.

5. The pharmaceutical preparation according to claim 1, It is characterized in that The concentration of the tryptase monoclonal antibody in the pharmaceutical preparation is 1-40 mg / ml.

6. The pharmaceutical preparation according to claim 1, It is characterized in that The buffer in the pharmaceutical preparation is selected from one or more of a citrate buffer and a phosphate buffer; Preferably, the concentration of the buffer solution is 5 to 25 mmol / L.

7. The pharmaceutical preparation according to claim 1, It is characterized in that The protein protective agent in the pharmaceutical preparation is one or more selected from surfactants, polyol dispersants, sugars, salts, amino acids, and polymers; Preferably, the concentration of the protein protective agent in the pharmaceutical preparation is 10-200 mg / ml.

8. The pharmaceutical preparation according to any one of claims 1 to 7, It is characterized in that The pharmaceutical preparations include nasal sprays.

9. Use of the pharmaceutical preparation according to any one of claims 1 to 8 in the preparation of a medicament for treating tryptase-related diseases.

10. The use according to claim 9, It is characterized in that The disease comprises at least one selected from pulmonary disease, autoimmune disease, inflammatory disease, fibrotic disease, granulocytic disease, monocytic disease, lymphocytic disease, or a disease associated with an increase in the number or distribution of normal or abnormal tissue resident cells or stromal cells; Preferably, the pulmonary disease comprises at least one selected from asthma, airway hyperresponsiveness and chronic obstructive pulmonary disease; Preferably, the asthma is high Th2 asthma or low Th2 asthma; Preferably, the autoimmune disease comprises at least one selected from rheumatoid arthritis, psoriasis, eosinophilic esophagitis, inflammatory bowel disease and Crohn's disease; Preferably, the inflammatory disease comprises at least one selected from chronic idiopathic urticaria, anaphylaxis, allergic shock, atopic dermatitis or allergic rhinitis; Preferably, the fibrotic disease is idiopathic pulmonary fibrosis; Preferably, the disease comprises mastocytosis.

Citation Information

Patent Citations

  • Anti-IL-23p19 antibodies

    CN104507497A

  • Administration of anti-tryptase antibodies

    CN117897409A

  • Antibodies against human trypsin and uses thereof

    CN118324919A